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Background. We have previously shown that interstitial
plaque particles appear first in the basement membranes of
thin loops of Henle and then in the interstitial space. How-
ever, it is not known if the plaque in the basement membrane
of thin loops of Henle is of the same or different form than the
interstitial plaque. Thus our purpose here is to detail the struc-
ture of the interstitial and membrane-bound plaque and explore
the relationship of plaque apatite to osteopontin, a well-known
crystal-associated urine protein.
Methods. Deep papillary biopsy tissue was studied from all
15 calcium oxalate stone formers and four nonforming subjects
that we previously reported on [Evan et al, J Clin Ivest, 2003].
Routine light and transmission electron microscopy (TEM) as
well as light microscopy and TEM immunohistochemical lo-
calization of osteopontin antibody were performed on all 19
subjects.
Results. In the basement membrane, plaque particles are in-
dividual and appear laminated with alternating light regions of
crystal and electron-dense organic layers. In the interstitium, in-
dividual particles are not abundant but are instead aggregated
to form regions of attached particles and in some regions what
appears to be a fusion or syncytium in which crystal islands float
in an organic sea. By light microscopy immunohistochemistry,
osteopontin was localized to cells of the loops of Henle and col-
lecting ducts as well as on sites of plaque. By immunoelectron
microscopy, osteopontin immunogold label was found mainly
on the surfaces of apatite crystal phase, at the junction of the
crystal/organic layers. A similar immunogold labeling pattern
was seen in the particles forming the syncytial islands of inter-
stitial plaque.
Conclusion. If indeed we accept the hypothesis that apatite
plaque may be an anchored site on which calcium oxalate stones
form and grow, the present work makes clear that it is unlikely
that the surface of plaque presented to the final urine will be
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apatite crystal per se. However, our findings clearly show osteo-
pontin is one of the crystal-associated urine proteins involved
in the formation of the organic layers of the plaque particles.
Elsewhere [1] we have shown that interstitial apatite
plaque particles appear to first form in the basement
membranes of the thin loops of Henle. In addition, we
have shown that plaque formation appears related to wa-
ter conservation, hypercalciuria, and an acid urine pH [2],
as one might expect if plaque originated because of super-
saturations with respect to calcium phosphate in thin limb
lumens or renal papillary interstitium [3]. For many years,
apatite plaque has been considered as a potential surface
on which calcium oxalate might grow to form a renal stone
[4]. A reasonable formulation at the present time would
presume plaque forms in thin limb basement membranes,
and expands its range through the papillary interstitium,
eventually reaching the suburothelial compartment, per-
haps breaching the urothelium, and presenting its surface
to the final urine.
Many elements of this general hypothetic mechanism
for stone pathogenesis are at present incompletely spec-
ified. In particular, the detailed structure of plaque par-
ticles is known only superficially. Whether plaque in the
thin limb basement membranes and in the papillary inter-
stitium is of the same or different form is not as yet known.
Especially important is the nature of the molecules that
associate with the apatite in plaque. Urine, for example,
contains many molecules that bind to calcium crystals
and can affect crystallization [5–9]; some or all of these
may associate with plaque. Our purpose here is to present
the detailed structure of human renal apatite interstitial
and membrane-bound plaque, and explore the relation-
ship to plaque apatite of osteopontin, a well-known and
well-defined crystal-associated urine protein.
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METHODS
Patients and materials
We studied deep medullary tissue from all 15 cal-
cium oxalate stone-forming patients and four control
nonstone-forming subjects we have previously reported
[1]. For this work, we have focused on the details of
plaque particle morphology and ultrastructure. Immuno-
histochemical techniques were used to study osteopontin
localization in tissue from all 19 subjects. We present rep-
resentative sections here, but have in all cases found sim-
ilar patterns in the remaining cases.
Light microscopy
General. Human biopsy samples were taken during
surgery and fixed in 5% fresh paraformaldehyde as pre-
viously reported [1]. Samples were dehydrated through
graded ethanol concentrations to 100% ethanol and
cleared in xylene before being embedded in a 50/50 mix-
ture of Paraplast Xtra (Fisher Scientific, Itasca, IL, USA)
and Peel-Away Micro-Cut (Polysciences Inc., Warring-
ton, PA, USA). Ten serial sections were cut at 4 lm,
placed on charged glass slides (Fisher Scientific) and
stored at 4◦C. Half of the sections were stained with the
Yasue metal substitution method for calcium histochem-
istry while the remaining slides were used for osteopontin
immunolocalization. The Yasue method uses 5% aque-
ous silver nitrate and rubeanic acid to generate a dark
brown to black histochemical staining of calcium deposits
[10].
Osteopontin immunolocalization. Osteopontin im-
munohistochemistry was preformed according to the
peroxidase-antiperoxidase (PAP) method as we reported
in our previous study [10]. The paraffin slides were de-
paraffinized and rehydrated through graded alcohols and
blocked for nonspecific protein binding using 20% nor-
mal goat serum in 0.1 mol/L phosphate-buffered saline
(PBS) at room temperature for 2 hours. The primary an-
tibody was LFMb-14, a mouse monoclonal osteopontin
antibody, a gift from Dr. Larry Fisher at NIH that was
used at a 1:100 dilution, or mouse monoclonal 2A1. The
secondary antibody was biotinylated goat antimouse IgG
(Sigma Chemical Co., St. Louis, MO, USA). Reactivity
was detected with the ELITE ABC kit (Vector Labora-
tories, Burlingame, CA, USA) and 3,3-diaminobezidine
(DAB) tetrahydrochloride. DAB in Tris-HCl buffer was
used as the chromogen. All sections were covered with
DAB solution (0.05 mol/L Tris-HCl, 0.001% hydrogen
peroxide, and 0.10% DAB), and incubated for approxi-
mately 10 minutes. Finally, each slide was rinsed well with
buffer and lightly counterstained with hematoxylin. Con-
trols were preformed with the elimination of the primary
antibody and showed no staining.
Transmission electron microscopy (TEM)
Another set of 5 mm samples were taken during
surgery, fixed in fresh 5% paraformaldehyde in phos-
phate buffer (pH 7.4) and divided in 1 mm blocks for
either routine TEM or osteopontin immunoelectron mi-
croscopic analysis.
All tissue blocks used for routine TEM analysis were
rinsed in phosphate buffer, dehydrated through a series of
graded ethanol concentrations to 100% ethanol, passed
through two changes of propylene oxide, and embedded
in Epon 812 (Electron Microscopy Science, Ft. Washing-
ton, PA, USA). Thick sections (approximately 1 lm) were
mounted on glass slides and stained with toluidine blue,
whereas the thin sections (approximately 0.04 lm) were
stained with uranyl acetate and lead citrate.
All tissue blocks used for immunoelectron micro-
scopic analysis were dehydrated through series of graded
ethanol concentrations to 100% ethanol, and embedded
in Unicryl (Electron Microscopy Science). Thick sections
(approximately 1 lm) were mounted on glass slides and
stained with toluidine blue. Ultrathin sections were cut at
0.07 lm and placed on formvar/carbon coated 200 mesh
nickel grids (Electron Microscopy Science). Each grid
was then processed for immunogold labeling. Grids were
floated on a drop of 0.05 mol/L glycine in PBS for 30 min-
utes to block residual aldehyde groups, followed by three
rinses in PBS. To prevent nonspecific binding, grids were
floated on a drop of blocking buffer [2% bovine serum
albumin (BSA), 0.1% Cold Water Fish Gelatin, 0.1%
Tween-20, and 8% sucrose in PBS] for 1 hour, then picked
up and the edge touched to filter paper to wick off as much
liquid as possible. Subsequently, the grids were incubated
overnight at 4◦C in primary antibody diluted 1 to 100 in in-
cubation buffer (0.1% BSA and 0.05% Tween-20 in PBS).
Primary antibody was LFMb-14, a mouse monoclonal os-
teopontin antibody, a gift from Dr. Larry Fisher at NIH.
Each grid was rinsed in three changes of the incubation
buffer prior to incubation in secondary antibody. The sec-
ondary antibody was goat antimouse conjugated with 10
nm gold particles that had been conjugated to a universal
secondary antibody Protein A (Electron Microscopy Sci-
ence). Exposure to the secondary antibody was followed
by postfixation in 2.5% glutaraldehyde in 0.1 mol/L phos-
phate buffer, and six rinses in distilled water. In order to
visualize the cellular membranes, individual grids were
floated on a drop of 1% osmium in distilled water and
rinsed well. For contrast, grids were stained with uranyl
acetate and lead citrate, rinsed and air dried in Petri dishes
lined with filter paper.
All grids used for routine TEM and immunoelectron
analysis were viewed with an FEI G2 Tecnai 12 BioTwin
TEM (FEI, Hillsboro, OR, USA), equipped with an
XR-60 Digital CCD system (AMT Corp., Danvers, MA,
USA).
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Fig. 1. Crystal deposition in basement membrane of loops of Henle observed by light microscopy. (A) Low magnification light micrograph showing
sites of Yasue-positive staining indicating regions of calcium deposits. Deposition is localized to the loops of Henle (arrows). (B and C) Higher-
magnification micrographs taken from panel a (see rectangles) to show that the deposits are localized to the basement membrane of the loops of
Henle (arrows) and then trailing into the interstitium (∗) [magnification, ×600 (A); ×1100 (B); and ×1100 (C)].
RESULTS
Routine light and TEM
General plaque topography. Visualized by Yasue stain
(Fig. 1A), plaque deposits center about thin limbs (ar-
rows) with little involvement of collecting ducts or ves-
sels. In focal areas (asterisks) particles migrate into the
surrounding interstitium, remaining in contiguity with the
basement membrane of the thin limb (Fig. 1B and C).
Gradual interstitial extension and enlargement appears
in some regions (Fig. 1B).
Basement membrane vs. interstitial plaque. In base-
ment membranes, plaque particles are individual and
laminated (Fig. 2A). Light regions within particles rep-
resent crystal, which we have already established as bio-
logic apatite [1]. The electron-dense rings represent what
we assume to be an organic layer based on prior studies of
kidney stones [11, 12]. This figure is representative of all
regions of basement membrane plaque. Even the smallest
deposits have a central light region of crystal enveloped
by organic material. Larger deposits have multiple alter-
nating rings of crystal and organic layers (Fig. 2). Under
high magnification TEM, the microcrystallite character
of the solid phase is easily seen (Fig. 2B).
In the interstitium, individual particles are not abun-
dant. Instead particles are aggregated to form regions of
attached particles, and in some regions what appears to be
a fusion, or syncytium in which crystal islands float in an
organic sea (Fig. 3). Some regions of interstitial plaque are
dominated by the syncytium pattern of the organic layer
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Fig. 2. Crystal deposition in basement membrane of loops of Henle observed by transmission electron microscopy. This set of transmission electron
micrographs shows the initial sites of crystal deposition in a calcium oxalate stone former. The deposits are single spheres with a multilaminated
internal morphology consisting of a central light region of crystalline material surrounded by a dark layer of matrix material (A). These layers
alternate as many as six to seven times. This internal morphology is clearly seen in the higher magnification transmission electron microscopy (B)
[magnification, ×25,000 (A); and ×70,000 (B)].
(Fig. 3C and D). In all regions, crystals are surrounded by
a rim of organic material; it is the organic material that
appears to form the continuous matrix in which crystals
occur as more or less separate regions of limited size.
Regions of particle fusion. In many areas we can find
extensive fields of individual particles that have aggre-
gated together but remain identifiable as individual de-
posits (Fig. 3A). At high magnification, fusion of particles
is demonstrated (Fig. 3B, arrows). As well, fusion areas
forming a syncytium are clearly seen (Fig. 3C and D, ar-
row). We are concerned in this work with fusion of coated
crystal particles and not with whether or not apatite crys-
tal does or does not undergo aggregation. The specific
behavior of the crystal phase itself would require studies
other than those presented here.
Osteopontin immunolocalization
Light microscopy. In deep medulla of kidney from a
normal human subject osteopontin antibody localizes in
the cells of the inner medullary collecting ducts and thin
loops of Henle (Fig. 4A and B). We have found this same
exact pattern in three other normal subjects (not shown).
In deep medulla from a calcium oxalate stone-forming
patient (Fig. 4C and D) osteopontin antibody localizes in
the cells of collecting ducts and thin loops of Henle as in
the normals. Intensity of cellular staining for osteopontin
did not differ in stone formers vs. controls, or in areas
with plaque vs. areas without plaque.
Osteopontin associates with plaque deposits as well as
with cells (Fig. 4C and D). Plaque deposits stained with
the Yasue stain are shown in a serial section (Fig. 4E) so
the relationship between osteopontin and plaque local-
ization can be visualized (compare Fig. 4D and E). This
pattern of colocalization of osteopontin antibody and in-
terstitial apatite plaque was seen in deep medulla from
all 15 calcium oxalate stone-forming patients (remainder
of patients not shown).
TEM. Osteopontin immunogold label in thin loop
basement membrane specifically localizes to individual
plaque particles (Fig. 5). Within individual crystalline par-
ticles (Fig. 5B and C), the osteopontin immunogold par-
ticles align themselves mainly on the surfaces of the ap-
atite crystal phase, at the junction of the crystal and its
organic coating layer. At higher resolution (Fig. 5D) this
specific localization is particularly clear. What we show
in these examples is representative of all sections thus far
studied.
The osteopontin immunogold label in the interstitium
shows a similar pattern. Within particle aggregates, os-
teopontin immunogold label often aligns closely with the
crystal organic interfacial regions, conforming to the ir-
regular outlines of the apatite phases (Fig. 6). Within
syncytial regions (Fig. 6A and B) immunogold parti-
cles associate strongly with the islands of apatite phase;
few immunogold particles can be seen in regions de-
void of apatite. At high resolution (Fig. 6C and D),
areas of apatite crystal are surrounded by osteopontin
immunogold label, forming in some cases a double layer
of immunogold particles around a ring of apatite crystal
(arrows).
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Fig. 3. Sites of interstitial plaque. The individual particles aggregate into twos, threes, and fours and into larger clumps of attached particles (A
and B, arrows). The result is crystal islands embedded in an organic layer (C and D) [magnification, ×13,000 (A); ×60,000 (B); ×12,000 (C); and
×13,000 (D)].
DISCUSSION
Formation and extension of plaque
We have already presented evidence that plaque orig-
inates in the basement membranes of the thin limbs [1].
This is the only region that always contains plaque when
any plaque is present, and the only region in which one
repeatedly finds plaque in isolation. At no time have we
ever found apatite crystals in the lumens of healthy thin
limbs whose basement membranes contain plaque, so we
have been forced to assume that plaque forms in the mem-
branes, rather than that apatite crystals form in the thin
loop lumens and migrate into the membranes. Here we
show for the first time evidence for extension of plaque
articles into the interstitium to form masses of interstitial
plaque that have contiguity with the thin limb basement
membranes.
The fact of the contiguity forces us to presume that
either the plaque has formed simultaneously in the base-
ment membranes and interstitium, or has migrated by ex-
tension from basement membrane into the interstitium.
Simultaneous formation is not attractive in that we often
find basement membrane plaque without surrounding in-
terstitial plaque but never the converse. Formation in the
interstitium and migration into the membrane is even less
acceptable in that we have never observed interstitial
plaque in contiguity with basement membranes devoid
of plaque whereas we regularly find plaque in basement
membranes whose surrounding interstitium is devoid of
plaque. This leaves us with membrane plaque formation
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Fig. 4. Light microscopic osteopontin staining in papillary biopsies from control (A and B) and calcium oxalate stone formers (C to E). (A) The
control tissue without the primary antibody while (B) is with the osteopontin antibody showing staining of the inner medullary collecting ducts
(arrow) and thin loops of Henle (double arrow). A set of serial sections of a calcium oxalate stone former (C to E). (C) The calcium oxalate tissue
without the primary antibody while the tissue in (D) is stained with the osteopontin antibody. Osteopontin is localized to inner medullary collecting
ducts (arrows) and thin loops of Henle (double arrows) as well as sites of crystal deposition (∗). (E) A serial section of the calcium oxalate patient
that has been stained with the Yasue method and shows positive sites (black to brown stain) of crystalline material that can be correlated with
osteopontin positive sites [magnification, ×600 (A); ×600 (B); ×60 (C); ×60 (D); and ×60 (E)].
and subsequent extension into interstitium as our primary
working hypothesis, but does not exclude simultaneous
formation in interstitium and basement membrane.
Basement membrane vs. interstitial plaque
The morphologies of plaque in membrane and inter-
stitium appear to favor membrane formation with sub-
sequent interstitial migration. In thin limb membranes
plaque is always particulate, whereas in the intersti-
tium it varies from aggregates of plaque particles to a
complete syncytium. We have presented evidence that
particles clearly fuse in pairs and higher groups to form
aggregates and the syncytium. Therefore, the most rea-
sonable provisional hypothesis is that in the regions
of contiguity we have shown here particles are mov-
ing out of the basement membranes, and fusing in the
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Fig. 5. Immunoelectron microscopic localization of osteopontin at loops of Henle. (A) A low-magnification transmission electron microscopy
showing immunogold label (arrows) indicating osteopontin localization within single crystals found in the basement membrane of loops of Henle
as well as in the interstitial plaques. (B to D) Higher-magnification transmission electron micrographs showing that osteopontin (arrows) is found
at the interface of the crystalline material and the organic layer [magnification, ×10,000 (A); ×20,000 (B); ×15,000 (C); and ×50,000 (D)].
interstitium to form the interstitial plaque configura-
tion. We are unaware of any prior demonstrations of the
plaque ultrastructure presented here.
The specific mechanisms of account for how parti-
cles appear to extend into the renal interstitium are not
known. We can envision four alternatives. Individual par-
ticles could physically migrate into the interstitium per-
haps by Brownian motion. Interstitial cells or possibly
migrating monocytes might take particles up and move
them. We have seen evidence for this. The interstitial cells
could create nucleating conditions with de novo forma-
tion of interstitial particle aggregates. Finally, crystal mass
within a region of basement membrane could enlarge and
physically extend by direct contiguity into the intersti-
tium. At the present time we cannot distinguish these,
but some of the micrographs support the last alternative.
Osteopontin
In the absence of plaque we have demonstrated deep
medulla osteopontin localization in the cells of thin limbs
and collecting ducts. A prior report [13] that did not have
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Fig. 6. Immunoelectron microscopic localization of osteopontin in interstitial plaque. (A) A low-magnification transmission electron micrograph
showing immunogold label (arrows) indicating osteopontin localization within the interstitial plaques. The immunogold label aligns closely with the
crystal organic interfacial regions, conforming to the irregular outlines of the apatite phases. At increasing magnifications (B to D), immunogold
particles form in some cases a double layer of immunogold label around a ring of apatite crystal (arrows) [magnification, ×9000 (A); ×14,000 (B);
×35,000 (C); and ×37,000 (D)].
extensive deep medulla tissue describes staining of oc-
casional collecting duct cells but does not comment on
thin limbs. This report may well be the first concerning
osteopontin in deep medulla of healthy humans. In nor-
mal rats, the pattern varies with the antibody employed
but thin limb and papillary epithelium are usual sites of
localization [14].
Osteopontin expression is up-regulated by many forms
of renal injury that have nothing to do with crystal forma-
tion [14, 15]. These include renal injury from drugs, hy-
pertension, obstruction, ischemia, and glomerulonephri-
tis. We did not find increased osteopontin in renal cells
adjacent to plaque particles compared to cells in areas
free of plaque particles, nor was cell osteopontin stain-
ing increased in tissue from the stone formers compared
to tissue from our controls. Therefore, at least this gauge
of renal injury did not suggest that plaque injures renal
cells.
Evan et al: Osteopontin in plaque particles 153
In areas of deep medulla that contain plaque, osteopon-
tin localizes strongly to plaque areas. Within these areas,
we find the antibody localizes specifically to the surfaces
of the apatite crystal. In plaque particles within basement
membranes, or areas of apatite in the interstitial plaque
syncytium, osteopontin localizes at the interface between
the apatite crystal phase and its surrounding organic
coating.
The affinity of osteopontin for apatite crystals is well
documented [12]. It is found in bone matrix in associa-
tion with bone mineral apatite [16]. It is associated with
mineral phases in pathologic vessel calcifications [17]. It
is found in the matrix of kidney stones [12]. It is an estab-
lished urinary inhibitor of calcium oxalate and calcium
phosphate crystallization [5, 18, 19]. In an osteopontin
knockout mouse given ethylene glycol to induce oxalate
production, calcium oxalate crystal formation was en-
hanced compared to the wild-type mouse [20]. In mice
lacking the sodium phosphate cotransporter gene Npt2
apatite crystals form in tubule lumens, and osteopon-
tin localizes primarily on the surfaces of apatite crystal
deposits [21]. Given what is known, it is not surprising
that we find this molecule localized at the apatite crystal
surface.
What role the molecule plays in plaque pathogenesis
is at present unknown. We presume its source is at least
from the cells of the thin limbs. It may simply adsorb to
apatite crystal surfaces of plaque and play no other role.
However, it is known to inhibit apatite crystal growth
[18, 22] and could be important in limiting the amount
of apatite crystal formed. Exogenous osteopontin limited
the extent of apatite formation in cultured bovine smooth
muscle cells [23]. On the other hand, when immobilized,
osteopontin can nucleate hydroxyapatite crystallization
[24]. Possibly both occur.
Implications for pathogenesis of calcium oxalate stones
If indeed we accept the general hypothesis that apatite
plaque may be an anchored site on which calcium oxalate
stones form and grow, the present work makes clear that
it is unlikely that the surface of plaque presented to the
final urine will be apatite crystal per se. We find all apatite
crystal in plaque is surrounded by an organic layer whose
composition is not presently known. It is this material
that is most likely to face the final urine. We did not find
osteopontin particularly located on the outer surface of
the organic layers of individual plaque particles in base-
ment membranes. In the interstitial plaque syncytium we
found osteopontin adsorbed to apatite, which is within
the organic material. Therefore, we are not able to say
that osteopontin is likely to face the final urine. Clearly
the nature of the organic layers of plaque is critical to an
understanding of what role plaque might play in calcium
oxalate stone genesis.
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